🇺🇸 FDA
Patent

US 10626145

Peptide with anti-obesity and anti-diabetes activity and use thereof

granted A61KA61K38/00A61K38/08

Quick answer

US patent 10626145 (Peptide with anti-obesity and anti-diabetes activity and use thereof) held by CAREGEN CO., LTD. expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CAREGEN CO., LTD.
Grant date
Tue Apr 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K38/00, A61K38/08, A61K38/2264, A61K38/30